In the article below ... prenatal diagnosis of CAH was first reported in 1965, based on elevated levels of amniotic fluid (AF) Androstenedione, 17-ketosteroids and pregnanetriol. But the mother had to stop taking the dex before the amniotic tests for a few days. And now (after 1985) doctors like the mother to stay on the dex and not stop, plus doctors think the DNA test is more reliable and is it not necessary to check the 17-ketosteroids and pregnanetriol levels in the fluids.

The amount of dex is VERY small amount and it should not affect the baby. It is a natural hormone that you body makes anyway. But if I were you, I would have the doctors check the amniotic fluids tested for the Androstenedione, 17-ketosteroids and pregnanetriol. As a double check so that you will know whether or not the little girl has CAH.  So you can stop the dex treatment if she does not have CAH. And if she does have CAH... she can be treated right away.

 Did you have the cells sent to Dr. Maria New in New York City? I had the CVS done locally and the cultures sent to NY. 

Title: Technical Report: Congenital Adrenal Hyperplasia.
Subject(s): ADRENOGENITAL syndrome; ADRENAL cortex -- Diseases
Source: Pediatrics, Dec2000, Vol. 106 Issue 6, p1511, 8p

ABBREVIATIONS. CAH, congenital adrenal hyperplasia; 21-OH,
21-hydroxylase; 17-OHP, 17alpha-hydroxyprogesterone; AF, amniotic
fluid; HLA, human leukocyte antigen; ACTH, adrenocorticotropic
hormone.

Prenatal diagnosis of CAH was first reported in 1965, based on elevated levels of amniotic fluid (AF) 17-ketosteroids and pregnanetriol.(n1) In 1975, the association between an elevated 17-OHP concentration in AF and the birth of an infant with salt-wasting CAH was reported.(n2) Subsequent reports have confirmed the usefulness of AF 17-OHP concentrations for the prenatal diagnosis of classic CAH attributable to 21-OH deficiency.(n3-n13) Although amniocentesis has been performed routinely during the second trimester in women at risk of having an infant with CAH, elevated 17-OHP levels in AF obtained as early as 9 to 13 weeks in pregnancies with an affected fetus have been reported. Androstenedione levels (Delta 4), which also are elevated in pregnancies in which the fetus is affected with CAH, provide another diagnostic measurement.

The preferred technique for prenatal diagnosis is molecular genetic analysis using DNA extracted from chorionic villus cells or amniocytes for analysis of CYP21B, C4 and HLA class I and II genes.(n18-n23) Advances in these molecular techniques have made genetic characterization more reliable and rapid,(n24) such that in most centers the analysis of fetal P450c21B genes from chorionic villus cells or amniocytes has largely replaced hormonal and HLA analysis in the prenatal diagnosis of CAH attributable to 21-OH deficiency.(n25)